tiprankstipranks
Trending News
More News >
Danaher Corp. (DHR)
NYSE:DHR

Danaher (DHR) AI Stock Analysis

Compare
2,888 Followers

Top Page

DH

Danaher

(NYSE:DHR)

Rating:72Outperform
Price Target:
$219.00
▲(8.71%Upside)
Danaher's overall stock score reflects a solid financial foundation with strong profitability and operational efficiency. However, valuation concerns, technical indicators showing mixed signals, and challenges in core revenue and specific segments temper the outlook. The earnings call highlights both achievements and potential risks, notably in geopolitical areas.
Positive Factors
Bioprocessing Trends
Bioprocessing trends are encouraging, with improving order trends and a solid B2B performance, indicating a positive outlook for market growth.
Merger and Acquisition Opportunities
Analyst sentiment suggests that shares can increase in value, driven by merger and acquisition opportunities.
Revenue Performance
Danaher Corporation's first-quarter revenue of $5.7 billion exceeded expectations, with all segments surpassing top-line forecasts.
Negative Factors
China VBP Headwinds
China VBP headwinds have seemingly accelerated, with DHR now calling for a $150M headwind in '25.
Guidance Reduction
Life sciences instruments showed a slight decline in guidance, which is attributed to adverse A&G dynamics.
Tariff Costs
Tariff and trade war concerns raise new questions, with management highlighting $350 million of incremental tariff costs this year.

Danaher (DHR) vs. SPDR S&P 500 ETF (SPY)

Danaher Business Overview & Revenue Model

Company DescriptionDanaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
How the Company Makes MoneyDanaher Corporation generates revenue through the sale of its diverse range of products and services across its three main operating segments. In the Life Sciences segment, revenue is derived from the sale of advanced scientific instruments and consumables used in research and development. The Diagnostics segment contributes through the provision of diagnostic instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment earns revenue from water quality analysis and treatment products, as well as product identification equipment and consumables. Danaher's growth and earnings are also supported by strategic acquisitions and partnerships, allowing for expansion into new markets and the enhancement of its product offerings. The company leverages its Danaher Business System, a set of tools and processes focused on continuous improvement and growth, to drive efficiency and innovation, further enhancing its profitability.

Danaher Key Performance Indicators (KPIs)

Any
Any
Recurring Revenue
Recurring Revenue
Measures the portion of revenue expected to continue in the future, indicating business stability and potential for sustained growth.
Chart InsightsDanaher's recurring revenue shows a recovery trend in 2024 after a dip in 2023, aligning with the company's strategic focus on innovation and robust consumables demand in bioprocessing. Despite challenges in the Life Sciences segment and geopolitical tensions in China, the company expects core revenue growth of 3% for the full year. The earnings call highlights strong cash flow and successful product launches, suggesting resilience and potential for long-term shareholder value despite current headwinds.
Data provided by:Main Street Data

Danaher Earnings Call Summary

Earnings Call Date:Apr 22, 2025
(Q1-2025)
|
% Change Since: 8.92%|
Next Earnings Date:Jul 22, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a balanced outlook with significant achievements in bioprocessing and strong cash flow generation. However, challenges persist in core revenue stagnation, Life Sciences segment decline, and geopolitical tensions affecting China operations.
Q1-2025 Updates
Positive Updates
Strong Start to Fiscal Year 2025
First-quarter revenue, earnings, and cash flow exceeded expectations, with revenue reaching $5.7 billion. Bioprocessing saw high-single-digit growth, and order books showed consistent positive momentum.
Bioprocessing Growth
Bioprocessing core revenue increased by 7% with low double-digit growth in consumables and commercial demand from large pharma and CDMO customers.
New Product Launches
Significant investments in long-term growth resulted in impactful product launches, including Cytiva's Xcellerex X-platform and Beckman Coulter Life Sciences' mosaic spectral detection module.
Strong Free Cash Flow
Generated $1.1 billion of free cash flow with a conversion ratio of more than 110%.
Negative Updates
Flat Core Revenue
Core revenue was flat year-over-year with a low-single-digit decline in North America and issues in China impacting diagnostics businesses.
Life Sciences Segment Decline
Core revenue in the Life Sciences segment decreased by 4% with softened demand in academic and government sectors, particularly in the United States.
Challenges in China
High-single-digit decline in China due to volume-based procurement and reimbursement changes impacting diagnostics businesses.
Adjusted Operating Profit Margin Decline
The adjusted operating profit margin of 29.6% declined by 50 basis points due to productivity investments to reduce structural costs.
Company Guidance
During Danaher Corporation's First Quarter 2025 Earnings Results Conference Call, the company reported first-quarter revenues of $5.7 billion, with core revenue flat year-over-year. The gross profit margin increased by 100 basis points to 61.2%, while the adjusted operating profit margin decreased by 50 basis points to 29.6%. Adjusted diluted net earnings per share were $1.88, and free cash flow was $1.1 billion, resulting in a free cash flow to net income conversion ratio exceeding 110%. The company raised its full-year bioprocessing growth expectation to high-single digits, driven by robust consumables demand. However, life sciences guidance was adjusted to flat growth due to a softer academic and government market, particularly in the U.S., and volume-based procurement impacts in China. Danaher expects core revenue growth of approximately 3% for the full year, with a second-quarter adjusted operating profit margin target of around 25.5%. The company also initiated full-year adjusted EPS guidance between $7.60 and $7.75, emphasizing its strategic focus on innovation, customer support, and long-term shareholder value.

Danaher Financial Statement Overview

Summary
Danaher demonstrates strong profitability with healthy margins and a solid balance sheet. The stable financial outlook is supported by operational efficiency and strong cash generation capabilities, despite a recent decline in revenue and free cash flow growth.
Income Statement
76
Positive
Danaher's revenue growth has been stable but shows a decline in the recent TTM period. The gross profit margin for TTM is approximately 59.7%, and the net profit margin is around 15.8%, both indicating strong profitability. However, the revenue has slightly decreased compared to previous periods, affecting the overall growth outlook. EBIT and EBITDA margins remain healthy, reflecting operational efficiency.
Balance Sheet
82
Very Positive
The company maintains a solid balance sheet with a debt-to-equity ratio of approximately 0.32, suggesting moderate leverage. The return on equity (ROE) for TTM is about 7.4%, indicating efficient use of equity. The equity ratio is robust at approximately 64.3%, signifying a strong equity base relative to its assets, which enhances financial stability.
Cash Flow
74
Positive
Free cash flow has shown a decline in the TTM period, impacting the growth rate. However, the operating cash flow to net income ratio is 1.66, indicating strong cash conversion. The free cash flow to net income ratio is 1.30, reflecting solid cash generation relative to profits despite a decreasing trend in free cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue23.82B23.88B23.89B31.47B29.45B22.28B
Gross Profit14.23B14.21B14.03B18.95B17.95B12.47B
EBITDA7.17B7.28B7.50B9.71B10.01B6.59B
Net Income3.77B3.90B4.76B7.21B6.43B3.65B
Balance Sheet
Total Assets79.12B77.54B84.49B84.35B83.18B76.16B
Cash, Cash Equivalents and Short-Term Investments1.99B2.08B5.86B6.00B2.59B6.04B
Total Debt16.48B16.00B19.54B19.68B22.18B21.20B
Total Liabilities28.26B27.99B31.00B34.26B38.01B36.38B
Stockholders Equity50.85B49.54B53.49B50.08B45.17B39.77B
Cash Flow
Free Cash Flow4.90B5.30B5.78B7.37B7.06B5.42B
Operating Cash Flow6.25B6.69B7.16B8.52B8.36B6.21B
Investing Cash Flow-1.90B-1.98B-7.08B-2.23B-12.99B-21.24B
Financing Cash Flow-9.51B-8.38B-273.00M-2.57B1.29B1.01B

Danaher Technical Analysis

Technical Analysis Sentiment
Positive
Last Price201.46
Price Trends
50DMA
194.64
Positive
100DMA
199.56
Positive
200DMA
223.80
Negative
Market Momentum
MACD
1.50
Negative
RSI
57.58
Neutral
STOCH
54.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DHR, the sentiment is Positive. The current price of 201.46 is above the 20-day moving average (MA) of 196.96, above the 50-day MA of 194.64, and below the 200-day MA of 223.80, indicating a neutral trend. The MACD of 1.50 indicates Negative momentum. The RSI at 57.58 is Neutral, neither overbought nor oversold. The STOCH value of 54.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DHR.

Danaher Risk Analysis

Danaher disclosed 43 risk factors in its most recent earnings report. Danaher reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Danaher Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$42.66B49.0159.33%5.56%4.66%
AA
79
Outperform
$33.70B29.2618.88%0.84%0.56%-4.08%
WAWAT
73
Outperform
$21.12B32.1840.82%2.57%8.31%
DHDHR
72
Outperform
$143.85B38.287.22%0.64%-9.19%-12.75%
TMTMO
72
Outperform
$155.02B23.7313.73%0.42%0.96%9.19%
65
Neutral
€7.29B20.700.61%1.92%1.18%-29.88%
MTMTD
64
Neutral
$24.79B29.76-680.23%1.18%12.34%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DHR
Danaher
201.46
-47.48
-19.07%
A
Agilent
119.42
-9.25
-7.19%
IDXX
Idexx Laboratories
527.78
40.58
8.33%
MTD
Mettler-Toledo
1,193.31
-204.28
-14.62%
TMO
Thermo Fisher
412.12
-139.08
-25.23%
WAT
Waters
354.91
64.79
22.33%

Danaher Corporate Events

Executive/Board ChangesShareholder Meetings
Danaher Approves Key Proposals at Shareholder Meeting
Positive
May 8, 2025

On May 6, 2025, Danaher Corporation held its annual shareholder meeting where key proposals were voted on, including the election of thirteen directors and the ratification of Ernst & Young LLP as the independent accounting firm for 2025. The meeting also saw the approval of the executive compensation package, reflecting shareholder support for the company’s leadership and strategic direction.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025